Takeda's Zasocitinib Receives FDA Priority Review for Psoriasis Treatment
Takeda Pharmaceutical (NYSE:TAK) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for zasocitinib under priority review, with a target action date in early 2027. The drug is being evaluated as an oral treatment for adults with moderate-to-severe plaque psoriasis. Zasocitinib inhibits TYK2 kinase and showed strong efficacy in Phase 3 trials compared to placebo and existing treatments like apremilast and deucravacitinib. The pivotal LATITUDE PsO studies demonstrated that over 70% of patients achieved clear or almost clear skin at week 16, significantly outperforming the control groups. However, safety concerns remain as adverse events were reported in a majority of trial participants. Market success will depend on regulatory approval, prescribing patterns, and competitive dynamics with other oral and injectable therapies. Hedge fund interest has increased slightly since early 2026, suggesting cautious optimism among investors.
Tickers: $TAK